Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

REGENXBIO (RGNX) Revenue: 2014-2025

Historic Revenue for REGENXBIO (RGNX) over the last 11 years, with Sep 2025 value amounting to $29.7 million.

  • REGENXBIO's Revenue rose 22.88% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 91.30%. This contributed to the annual value of $83.3 million for FY2024, which is 7.66% down from last year.
  • As of Q3 2025, REGENXBIO's Revenue stood at $29.7 million, which was up 39.21% from $21.4 million recorded in Q2 2025.
  • REGENXBIO's Revenue's 5-year high stood at $398.7 million during Q4 2021, with a 5-year trough of $15.6 million in Q1 2024.
  • Over the past 3 years, REGENXBIO's median Revenue value was $22.2 million (recorded in 2023), while the average stood at $28.5 million.
  • Its Revenue has fluctuated over the past 5 years, first surged by 1,758.96% in 2021, then crashed by 92.14% in 2022.
  • Quarterly analysis of 5 years shows REGENXBIO's Revenue stood at $398.7 million in 2021, then crashed by 92.14% to $31.3 million in 2022, then fell by 29.13% to $22.2 million in 2023, then decreased by 4.50% to $21.2 million in 2024, then increased by 22.88% to $29.7 million in 2025.
  • Its Revenue was $29.7 million in Q3 2025, compared to $21.4 million in Q2 2025 and $89.0 million in Q1 2025.